Cerebral palsy

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
5 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
A Gastroenterology (ATC A) 1
M Musculoskeletal (ATC M) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Erythropoietin analogue 1 substance
Phase III: 1 Phase II: 1 Phase IV: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Neurocrine Biosciences Inc. Commercial
    VALBENAZINE DITOSYLATE 
    2022-502713-29-00 5 countries 2024 n=49
    Ended

Phase II

1 trial
  • Dompe' Farmaceutici S.p.A. Commercial
    CENEGERMIN
    2025-522786-29-00 1 country 2026 n=60
    Recruiting

Phase IV

2 trials
  • Hospices Civils De Lyon Academic
    BOTULINUM TOXIN TYPE A; HYOSCINE
    2024-512160-58-00 1 country 2025 n=132
    Ended
  • UZ Leuven Academic
    BACLOFEN
    2024-518822-33-01 2 countries n=48
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Dompe' Farmaceutici S.p.A. Commercial 1 Phase II 1
Neurocrine Biosciences Inc. Commercial 1 Phase III 0
Hospices Civils De Lyon Academic 1 Phase IV 0
UZ Leuven Academic 1 Phase IV 0
New trials by year
2024
1
2025
1
2026
1
← All indication landscapes